Inactive Instrument

VIVUS, Inc.

VVUSQ

US9285513084

Vivus: 1Q Earnings Snapshot

May 07, 2020 at 10:16 am

CAMPBELL, Calif. (AP) _ Vivus Inc. (VVUS) on Wednesday reported a loss of $5.2 million in its first quarter.

On a per-share basis, the Campbell, California-based company said it had a loss of 49 cents.

The biopharmaceutical company posted revenue of $19.6 million in the period.

The company's shares closed at $1.18. A year ago, they were trading at $3.97.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS

Automated Insights, source Associated Press News

Latest news about VIVUS, Inc.

Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	05-30	CI
VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	04-22	CI
VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	11-28	CI
VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development	10/01/23	CI
FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	20/07/22	CI
VIVUS, Inc. Emerged from Bankruptcy	11/12/20	CI
Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc.	10/12/20	CI
First Motion for Exclusivity Period Extension Approved For VIVUS, Inc.	17/11/20	CI
Second Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	10/11/20	CI
First Motion for Exclusivity Period Extension Filed by VIVUS, Inc.	04/11/20	CI
Motion for Asset Sale Filed by VIVUS, Inc.	20/10/20	CI
First Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	18/08/20	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from S&P TMI Index	10/07/20	CI
Motion for Joint Administration Approved for VIVUS, Inc.	10/07/20	CI
Combined Hearing for Disclosure Statement and Plan Approved for VIVUS, Inc.	10/07/20	CI
Health Care Flat As Growth Investors Seek Out Tech -- Health Care Roundup	08/07/20	DJ
VIVUS, Inc. Appoints Jill Frizzley as a Independent Director of the Company	07/07/20	CI
VIVUS, Inc. Filed for Bankruptcy	07/07/20	CI
Motion for Joint Administration Filed by VIVUS, Inc.	07/07/20	CI
Joint Pre-Packaged Reorganization Plan and Disclosure Statement Filed by VIVUS, Inc.	07/07/20	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Index	26/06/20	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Value Index	26/06/20	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Growth Index	26/06/20	CI
VIVUS, Inc. Contemplates Bankruptcy	02/06/20	CI
Transcript : VIVUS, Inc., Q1 2020 Earnings Call, May 06, 2020	06/05/20

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+39.82%	734B
NOVO NORDISK A/S	+31.34%	591B
JOHNSON & JOHNSON	-7.31%	350B
MERCK & CO., INC.	+14.23%	315B
ABBVIE INC.	+0.86%	276B
ASTRAZENECA PLC	+13.47%	238B
ROCHE HOLDING AG	-6.63%	204B
NOVARTIS AG	+7.49%	206B
AMGEN INC.	+4.51%	161B

Other Pharmaceuticals